Treatment of Imiquimod Resistant Epidermodysplasia Verruciformis With Ingenol Mebutate.
| Autor: | Kim C, Hashemi P, Caglia M, Shulman K |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of drugs in dermatology : JDD [J Drugs Dermatol] 2016 Mar; Vol. 15 (3), pp. 350-2. |
| Abstrakt: | Background: Epidermodysplasia verruciformis (EV) is a rare genetic disorder characterized by widespread human papillomavirus (HPV) associated lesions and an increase susceptibility to cutaneous malignancies. A host of medications traditionally used to treat warty lesions have been used with variable results and limited success. To our knowledge, we describe the first reported case of a patient with Imiquimod resistant EV successfully treated with topical ingenol mebutate (Picato). Case: A patient with a 5 year history of EV failed to respond to a 6 week course of 5% imiquimod on the forehead and was subsequently treated with a 3 day course of 0.015% Picato gel which resulted in significant clinical improvement. A one month follow-up examination showed no reoccurrence of the lesions with the patient reporting continued satisfaction of the outcome. Conclusion: Our case provides insight into the potential use of ingenol mebutate for EV patients unresponsive to traditional medical treatments. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|